Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avinger Inc (AVGR)

Avinger Inc (AVGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,042
  • Shares Outstanding, K 10,351
  • Annual Sales, $ 7,920 K
  • Annual Income, $ -27,560 K
  • 60-Month Beta 1.74
  • Price/Sales 1.69
  • Price/Cash Flow N/A
  • Price/Book 1.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.10
  • Growth Rate Est. (year over year) +32,325.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.87 +45.65%
on 11/14/19
1.63 -22.70%
on 11/21/19
+0.28 (+28.57%)
since 11/13/19
3-Month
0.77 +63.64%
on 10/10/19
1.63 -22.70%
on 11/21/19
+0.13 (+11.50%)
since 09/13/19
52-Week
0.77 +63.64%
on 10/10/19
12.60 -90.00%
on 04/10/19
-2.06 (-62.05%)
since 12/13/18

Most Recent Stories

More News
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

QLYS : 85.08 (+0.37%)
CYBR : 126.35 (+3.02%)
AVGR : 1.26 (-2.33%)
ONVO : 0.50 (-1.88%)
ALXN : 110.42 (-1.82%)
What Bargain Hunting? Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E for outsized gains.

QLYS : 85.08 (+0.37%)
CYBR : 126.35 (+3.02%)
AVGR : 1.26 (-2.33%)
ALXN : 110.42 (-1.82%)
ONVO : 0.50 (-1.88%)
Avinger: 3Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Avinger Inc. (AVGR) on Tuesday reported a loss of $4.6 million in its third quarter.

AVGR : 1.26 (-2.33%)
Avinger Reports Third Quarter 2019 Financial Results

Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin Expansion

AVGR : 1.26 (-2.33%)
Try Rising P/E Investing With 5 Top-Ranked Stocks

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

TRIP : 29.25 (-0.68%)
NOW : 272.98 (+2.76%)
CHKP : 113.31 (-0.40%)
AVGR : 1.26 (-2.33%)
ALXN : 110.42 (-1.82%)
Avinger to Announce Third Quarter 2019 Financial Results on November 5, 2019

REDWOOD CITY, CA / ACCESSWIRE / October 29, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system...

AVGR : 1.26 (-2.33%)
Avinger (AVGR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

AVGR : 1.26 (-2.33%)
Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

SPSC : 56.18 (+1.10%)
SWKS : 111.86 (+0.33%)
VAR : 141.53 (-0.23%)
AVGR : 1.26 (-2.33%)
TUES : 1.81 (-1.63%)
Avinger Announces Full Commercial Launch of Pantheris SV

Product Shipped to 25 U.S. Accounts

AVGR : 1.26 (-2.33%)
Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24

REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that...

AVGR : 1.26 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AVGR with:

Business Summary

Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company's product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City,...

See More

Key Turning Points

2nd Resistance Point 1.34
1st Resistance Point 1.30
Last Price 1.26
1st Support Level 1.21
2nd Support Level 1.16

See More

52-Week High 12.60
Fibonacci 61.8% 8.08
Fibonacci 50% 6.69
Fibonacci 38.2% 5.29
Last Price 1.26
52-Week Low 0.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar